Company like every other small company , not earning producing need money to continue studies etc..So Public Offering was done..
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units - Tetra Bio-Pharma
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units12/01/2021/NOT FOR DISTRIBUTION TO U.S.
NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA,
ON, Dec. 1, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company"
(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has entered into an agreement with Research Capital Corporation and Echelon Wealth Partners Inc., acting as co-lead agents and joint bookrunners (the "Agents", in connection with a marketed public offering of units of the Company (the "Units" for aggregate gross proceeds of up to $13,000,000 (the "Offering", at an indicative price of $0.18 per Unit, priced in the context of the market.
Each Unit will be comprised of one common share of the Company (a "Common Share" and one Common Share purchase warrant of the Company (a "Warrant". Each Warrant will entitle the holder thereof to purchase one Common Share at an indicative exercise price of $0.25, priced in the context of the market, for a period of 48 months following the closing of the Offering.
The Company has granted the Agents an option (the "Over-Allotment Option" to increase the size of the Offering by up to an additional number of Units, and/or the components thereof, that in the aggregate would be equal to approximately 15% of the total number of Units to be issued under the Offering, to cover over-allotments, if any, and for market stabilization purposes, exercisable at any time and from time to time up to 30 days following the closing of the Offering.
The net proceeds from the Offering will be used by the Company for clinical trials, working capital and general corporate purposes.The closing of the Offering is expected to occur on or about December 9, 2021 (the "Closing", or on such date as agreed upon between the Company and the Agents, and is subject to the Company receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange (the "Exchange" to list, on the date of Closing, the Common Shares and the Common Shares issuable upon exercise of the Warrants and compensation warrants thereon.
In addition, the Company will use commercial reasonable efforts to obtain the necessary approvals to list the Warrants on the Exchange as soon as reasonably after the Closing.In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement" to the Company's short form base shelf prospectus dated April 1, 2020 (the "Shelf Prospectus", with the securities regulatory authorities in each of the provinces of Canada, except Quebec. Copies of the Shelf Prospectus and, the Supplement to be filed in connection with the Offering, can be found on SEDAR at www.sedar.com. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering.
Prospective investors should read the Supplement and accompanying Shelf Prospectus and the other documents the Company has filed on SEDAR at www.sedar.com before making an investment decision. This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws
About Tetra Bio-PharmaTetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units - Tetra Bio-Pharma
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units12/01/2021/NOT FOR DISTRIBUTION TO U.S.
NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA,
ON, Dec. 1, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company"
(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has entered into an agreement with Research Capital Corporation and Echelon Wealth Partners Inc., acting as co-lead agents and joint bookrunners (the "Agents", in connection with a marketed public offering of units of the Company (the "Units" for aggregate gross proceeds of up to $13,000,000 (the "Offering", at an indicative price of $0.18 per Unit, priced in the context of the market. Each Unit will be comprised of one common share of the Company (a "Common Share"
and one Common Share purchase warrant of the Company (a "Warrant". Each Warrant will entitle the holder thereof to purchase one Common Share at an indicative exercise price of $0.25, priced in the context of the market, for a period of 48 months following the closing of the Offering. The Company has granted the Agents an option (the "Over-Allotment Option"
to increase the size of the Offering by up to an additional number of Units, and/or the components thereof, that in the aggregate would be equal to approximately 15% of the total number of Units to be issued under the Offering, to cover over-allotments, if any, and for market stabilization purposes, exercisable at any time and from time to time up to 30 days following the closing of the Offering. The net proceeds from the Offering will be used by the Company for clinical trials, working capital and general corporate purposes.The closing of the Offering is expected to occur on or about December 9, 2021 (the "Closing"
, or on such date as agreed upon between the Company and the Agents, and is subject to the Company receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange (the "Exchange" to list, on the date of Closing, the Common Shares and the Common Shares issuable upon exercise of the Warrants and compensation warrants thereon. In addition, the Company will use commercial reasonable efforts to obtain the necessary approvals to list the Warrants on the Exchange as soon as reasonably after the Closing.In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement"
to the Company's short form base shelf prospectus dated April 1, 2020 (the "Shelf Prospectus", with the securities regulatory authorities in each of the provinces of Canada, except Quebec. Copies of the Shelf Prospectus and, the Supplement to be filed in connection with the Offering, can be found on SEDAR at www.sedar.com. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement and accompanying Shelf Prospectus and the other documents the Company has filed on SEDAR at www.sedar.com before making an investment decision. This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws
About Tetra Bio-PharmaTetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.
